Oncolytics Biotech Inc T.ONC

ONCY appoints Patricia S. Andrews to Board of Directors

[Noteable]

Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, Sumitomo Pharma Oncology

Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.

"Sumitomo Pharma America represents an exciting opportunity to leverage each subsidiary's competitive strengths to create an innovative biopharma company with the scale, agility and efficiency needed for accelerated impact and patient-focused outcomes," said Myrtle Potter, current CEO of Sumitovant and future President and CEO of Sumitomo Pharma America. 

Sumitovant is a technology-driven biopharmaceutical company accelerating development and commercialization of new potential therapies for patients with rare conditions and other diseases. 

"Sumitomo Pharma America will be well positioned to accelerate the development of Sumitomo Pharma Oncology's portfolio, and address unmet needs for cancer patients," said Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, Sumitomo Pharma Oncology.

https://www.prnewswire.com/news-releases/sumitomo-pharma-subsidiary-companies-in-the-us-including-sumitomo-pharma-oncology-to-combine-and-form-sumitomo-pharma-america-301788413.html

[Noteable]

"Positive, early results from the Phase 1/2 GOBLET study in three gastrointestinal cancers - pancreatic, anal, and colorectal - showed that the combination of pelareorep and atezolizumab produced clinically meaningful improvements in response rates and survival timelines that are notably improved compared to historical results with no toxicity concerns. Translational data from studies in

[fox7mf]

As per sedi report on ceo.ca,  P. Andrews received an options grant of 45k, much like what was bestowed upon Rigby & Parsons. 45 thousand reasons to help finalize a lucrative deal in the next couple of weeks or months. 

[Noteable]

https://www.linkedin.com/in/patricia-andrews/details/experience/

[Noteable]

Contributor to process of hiring new CEO (2020) at GlycoMimetics co-founder’s retirement.

[Noteable]

Rachel King - Co-founder, retired CEO, and member of BOD of GlycoMimetics and now CEO of BIO https://www.linkedin.com/in/rachel-king-35697220/

[Noteable]

On December 05, 2023 the Biotechnology Innovation Organization (BIO) announced that industry leader and military veteran John F. Crowley will be its new President and CEO, effective March 4. He will replace Rachel King, a longtime BIO board member and industry trailblazer who has served as BIO’s CEO on an interim basis for the past year. https://www.bio.org/press-release/industry-leader-and

[canadafan]

Patricia gets appointed to BOD & price tanks. Someone assumes a link between the two events. " jinx"... Let's look a little broader. At open & for most of the day most major indexes were down. Perhaps that is Patricia's appointment fault. Lol Patricia as a new board member with he credentials, contacts & acumen, all good news for ONC. Like I said yesterday any

[Noteable]

Background: Patricia S. Andrews previously served as Chief Executive Officer for Sumitomo Pharma Oncology, Inc. (SMP Oncology), where she led the organization through the integration of its multiple predecessor companies. Under her leadership, the organization completed three Phase 3 trials and expanded the clinical pipeline from two programs to eight. Prior to SMP Oncology, Ms. Andrews served as